The Quest To End Alzheimer’s: Dale Bredesen #522｜By: DAVE ASPREY August 30, 2018
https://blog.bulletproof.com/dale-bredesen-522/
https://44uc8dkwa8q3f5b66w13vilg-wpengine.netdna-ssl.com/wp-content/uploads/2018/08/BPR-DaleBredesen.pdf
PDF14-15ページより

Dale:　I think the key is gonna be that, although we all agree that many of these approaches are helpful, we were not made to have insulin resistance, so forth and so on.
But you're absolutely right. If we're not careful, we can expose other problems. I'll tell you one we've run into with the treatment of cognitive decline.
We get people on, we drive them into mild ketosis, from 1.5 mm to 4 mm beta-Hydroxybutyrate.
We're getting rid of their insulin resistance, reestablishing insulin sensitivity, addressing their pathogens, addressing detox, all these things.
But what we found is that the people who have BMIs, typically below 20, as they're now decreasing their carbs,
they don't have the adipose tissue to produce the ketones that are supporting their cognition. What happens, they're the ones that actually have problems at the beginning.
And so we now often add exogenous ketones, or more MCT oil, things like that, to make sure that they actually check them.
We've had a few that will actually develop gut problems, lose weight, and actually take a step back in the cognitive decline before we address the fact that,
"Oh yeah, you guys are not able at this point to generate those endogenous ketones, so we in fact need to help you and get your weight up, liberalize your diet, cycle in and out of ketosis," all those sorts of things.